Technavio has announced its pipeline analysis report on the autism
market. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat autism.
This press release features multimedia. View the full release here:
Technavio has published a new report on the drug development pipeline for autism, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME
MARKET SNAPSHOT BEFORE PURCHASING
Autism: Market overview
Autism or autism spectrum disorder (ASD) is a developmental disability
that majorly affects the social interaction and communication of an
individual. It is a combination of genetic and environmental factors
that challenge an individual’s verbal skills and ability to respond. The
major symptom of autism is repetitive behavior that affects information
processing in the brain by altering nerve cells.
According to a senior market research analyst at Technavio, “Autism
is a neurodevelopmental disorder that is discovered during infancy and
childhood. It is characterized by multiple impairments such as reduced
eye contact, restricted interests, difficulties in communication, and
repetitive behavior. Autism makes it difficult for autistic children to
express themselves either through words, gestures, or common facial
Autism: Segmentation analysis
This market research report segments the autism market based on
therapies employed (monotherapy and unknown), RoA (oral, intranasal, IV,
transdermal, transnasal, topical, and unknown), therapeutic modalities
(small molecules, microbiome, stem cell, polyclonal antibody, peptide,
protein, enzyme, and unknown), targets for drugs under development (GABA
receptor, AMPA receptor, mGlu receptor, ADNP, cannabinoid receptor,
chymotrypsin, dopamine-2 receptor, LPS, NMDA receptor, Nrf2 and NF-kB,
oxytocin receptor, vasopressin receptor 1A, and unknown), and
recruitment status (recruiting, active not recruiting, completed, not
yet recruiting, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a
disease. In the current pipeline, around 11 molecules that are being
investigated for the treatment of autism are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through
the mouth cavity. About 13 molecules that are in the current pipeline
are expected to be administered orally.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST
A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
Drug Development Strategies
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005662/en/